Acadia Pharmaceuticals (ACAD) Consolidated Net Income (2010 - 2026)
Acadia Pharmaceuticals (ACAD) posted quarterly Consolidated Net Income of $3.7 million for Q1 2026, down 80.63% year-over-year from $19.0 million in Q1 2025, and down 92.05% quarter-over-quarter from $46.3 million in Q4 2025.
Acadia Pharmaceuticals (ACAD) Consolidated Net Income (2010 - 2026) Analysis & Trends
Acadia Pharmaceuticals' Consolidated Net Income history runs 17 years deep, the most recent figure standing at $3.7 million for Q1 2026.
- In Q1 2026, Consolidated Net Income fell 80.63% year-over-year to $3.7 million; the TTM figure through Mar 2026 stood at $148.4 million (down 41.69% YoY), while the FY2025 annual figure was $163.7 million, down 35.06% from the prior year.
- Consolidated Net Income for Q1 2026 stood at $3.7 million, down from $46.3 million in the prior quarter.
- The five-year high for Consolidated Net Income was $169.4 million in Q4 2024, with the low at -$113.1 million in Q1 2022.
- The 5-year median for Consolidated Net Income is $16.6 million (2024), against an average of $8.4 million.
- The sharpest annual moves came in 2023 and 2024: Consolidated Net Income plunged 139.62% in 2023, then soared 2897.22% in 2024.
- Acadia Pharmaceuticals' Consolidated Net Income stood at -$41.6 million in 2022, then jumped by 209.77% to $45.7 million in 2023, then soared by 270.6% to $169.4 million in 2024, then tumbled by 72.66% to $46.3 million in 2025, then slumped by 92.05% to $3.7 million in 2026.
- Business Quant data shows ACAD's Consolidated Net Income at $3.7 million in Q1 2026, $46.3 million in Q4 2025, and $71.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 930.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Acadia Pharmaceuticals | 4.86 Bn | 3.90 Bn | 279.64 Mn | 31.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 31.50 Mn |
| Mar 31, 2026 | 3.68 Mn |
| Dec 31, 2025 | 46.32 Mn |
| Sep 30, 2025 | 71.78 Mn |
| Jun 30, 2025 | 26.66 Mn |
| Mar 31, 2025 | 19.01 Mn |
| Dec 31, 2024 | 169.42 Mn |
| Sep 30, 2024 | 32.76 Mn |
| Jun 30, 2024 | 33.39 Mn |
| Mar 31, 2024 | 16.60 Mn |
| Dec 31, 2023 | 45.71 Mn |
| Sep 30, 2023 | -65.10 Mn |
| Jun 30, 2023 | 1.11 Mn |
| Mar 31, 2023 | -43.00 Mn |
| Dec 31, 2022 | -41.64 Mn |
| Sep 30, 2022 | -27.17 Mn |
| Jun 30, 2022 | -34.01 Mn |
| Mar 31, 2022 | -113.06 Mn |
| Dec 31, 2021 | -46.62 Mn |
| Sep 30, 2021 | -14.46 Mn |